Trials / Active Not Recruiting
Active Not RecruitingNCT04881916
Immune and Genomic Markers in ALK+ NSCLC
Elucidating Novel Immune and Genomic Markers for ALK (ENIGMA+)
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Massachusetts General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to obtain and study clinical history, and tissue and saliva specimens if available from participants with Anaplastic Lymphoma Kinase-ALK+ Non-Small Lung Cancer(NSCLC)
Detailed description
The purpose of this study is to establish a registry of clinical data and tumor specimens of patients with advanced ALK+ non-small lung cancer (NSCLC) (defined as NSCLC harboring an ALK gene rearrangement). This will allow in-depth, comprehensive genomic and immunophenotypic analyses of ALK+ tumors. Together with the clinical data, these biologic specimens will enable the conduct of basic and translational research to identify genomic and immunologic markers associated with clinical outcomes for ALK+ patients.
Conditions
Timeline
- Start date
- 2021-12-01
- Primary completion
- 2027-07-01
- Completion
- 2027-07-01
- First posted
- 2021-05-11
- Last updated
- 2026-03-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04881916. Inclusion in this directory is not an endorsement.